Your browser doesn't support javascript.
loading
Need for hyperlipidemia management policy reform in China: learning from the global experience.
Yu, Wei; Shi, Ruizhi; Li, Jim; Lan, Yong; Li, Qian; Hu, Shanlian.
Affiliation
  • Yu W; a Department of Medical Affairs , Pfizer , Beijing , China.
  • Shi R; a Department of Medical Affairs , Pfizer , Beijing , China.
  • Li J; b Department of Medical Affairs , Pfizer Inc. , San Diego , CA , USA.
  • Lan Y; a Department of Medical Affairs , Pfizer , Beijing , China.
  • Li Q; a Department of Medical Affairs , Pfizer , Beijing , China.
  • Hu S; c Shanghai Health Development Research Center , Fudan University , Shanghai , China.
Curr Med Res Opin ; 34(2): 197-207, 2018 02.
Article in En | MEDLINE | ID: mdl-28696793
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Preventive Health Services / Cardiovascular Diseases / Global Health / Health Policy / Hyperlipidemias / Hypolipidemic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Asia Language: En Journal: Curr Med Res Opin Year: 2018 Document type: Article Affiliation country: China Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Preventive Health Services / Cardiovascular Diseases / Global Health / Health Policy / Hyperlipidemias / Hypolipidemic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Asia Language: En Journal: Curr Med Res Opin Year: 2018 Document type: Article Affiliation country: China Country of publication: United kingdom